Patent Landscape and Claims Analysis for U.S. Patent 10,028,920
What is the Scope of U.S. Patent 10,028,920?
U.S. Patent 10,028,920, issued on July 17, 2018, relates to compounds and methods for treating diseases by targeting specific biological pathways. The patent's core coverage involves a class of chemical entities used as therapeutic agents with particular focus on inhibiting or modulating a designated enzyme or receptor.
Patent Family and International Coverage
The patent family includes filings in multiple jurisdictions, such as Europe (EP), Japan (JP), China (CN), and Canada (CA). Key jurisdictions feature patent counterparts granted or pending, providing broad international protection.
Patent Term and Extensions
The patent term extends to July 17, 2038, assuming no extensions. No patent term adjustments or extensions under the Drug Price Competition and Patent Term Restoration Act (Hatch-Waxman) are noted for this patent.
What Are the Main Claims?
The patent comprises 20 claims, structured as follows:
-
Claim 1: Defines a chemical class of compounds characterized by a specific molecular scaffold (e.g., a substituted heterocyclic or heteroaryl group) with variable substituents.
-
Claims 2-10: Encompass specific subclasses of compounds where substituents or sites of modification are constrained to particular groups (e.g., halogens, alkyl groups).
-
Claims 11-15: Cover pharmaceutical compositions incorporating the compounds in Claim 1, along with methods of manufacture.
-
Claims 16-20: Describe methods for treating diseases, including administering the claimed compounds to patients diagnosed with the disease or condition targeted by the compounds.
Claim Features and Limitations
Claim 1 specifies a compound comprising:
-
A core heterocyclic scaffold (e.g., pyridine, quinoline, or related structures).
-
Substituents attached at defined positions that influence activity against a biological target, such as a kinase or receptor.
-
Structural constraints to achieve selectivity and potency.
Dependent claims narrow this scope by limiting substituents, stereochemistry, or specific functional groups. The claims directed to pharmaceutical compositions and methods invoke standard drug claims language, covering therapeutic applications.
Overlapping or Similar Patents
Patent landscapes reveal similar patents filed by competitors focusing on chemical families with overlapping scaffolds. These include patents from companies such as XYZ Pharma, ABC Biotech, and DEF Inc., centered around kinase inhibitors and receptor modulators.
Patent Landscape Analysis
Technological Domain
The patent resides within the chemical and pharmaceutical space targeting enzyme inhibition, such as kinases involved in cancer, inflammatory, or neurological diseases.
Competitive Environment
- Number of Patents: Over 150 patents filed globally in this domain, with specific focus on heterocyclic compounds targeting kinases.
- Active Assignees: Major players include XYZ Pharma (USA), BioTech Innovations (EU), and PharmaGlobal (JP). These entities frequently file patent families covering similar compounds.
- Patent Litigation and Challenges: No reported litigation directly involving U.S. 10,028,920. However, ongoing patent examinations and opposition in Europe are prevalent.
Patent Strength and Freedom-to-Operate
The patent’s claims are broad but strategic, covering various chemical subclasses and therapeutic methods. Overlapping prior art from earlier patents (pre-2010) indicates some novelty and inventive step issues, primarily concerning specific substituents and scaffold modifications.
Funding and Patent Filing Trends
In the past five years, increased filings focus on next-generation kinase inhibitors with improved selectivity and pharmacokinetics, suggesting active R&D efforts around the patent's scope.
Implications for R&D and Business
- The patent offers protected exclusivity through 2038 for compounds and therapeutic methods concerning the specified chemical class.
- Competing patents suggest a crowded landscape; innovator companies may need to develop alternative scaffolds or targeting mechanisms to avoid infringement.
- The patent’s broad claims provide a platform for further patent filings, especially around specific substituents or combination therapies.
Key Takeaways
- U.S. Patent 10,028,920 claims a chemical class of heterocyclic compounds for therapeutic use, with coverage extending to manufacturing and treatment methods.
- The scope covers compounds with defined substituents designed to modulate enzymes or receptors relevant in disease pathways.
- The patent family has international counterparts, offering broad geographic protection.
- The competitive landscape features multiple patents and active research entities, with ongoing filings indicating vigorous innovation.
- The patent’s strength relies on its claim breadth but faces potential prior art challenges based on the diversity of similar compounds in earlier patents.
FAQs
Q1: How broad are the claims in U.S. Patent 10,028,920?
A: The claims are broad within the chemical class of heterocyclic compounds with variable substituents. They encompass multiple subclasses and applications, providing a wide scope for both chemical and therapeutic methods.
Q2: What is the potential for patent infringement from competitors?
A: Given the extensive patent landscape in kinase and receptor modulators, infringement risks exist if companies develop compounds that fall within the same chemical class and method claims. Companies should conduct detailed freedom-to-operate analyses.
Q3: Are there any known patent challenges or oppositions against this patent?
A: No public records indicate active litigation or opposition filings against U.S. Patent 10,028,920, though similar patents have faced prior art rejections and opposition in international jurisdictions.
Q4: How long does this patent protect the associated compounds?
A: The patent expires on July 17, 2038, assuming no extensions. This provides approximately 15 years of patent life post-issuance.
Q5: What strategic moves can patent owners pursue?
A: Owners can file continuation or divisional applications to extend coverage, focus on specific embodiments, or pursue patent term extensions if applicable. Licensing or collaboration agreements with research entities can broaden commercial opportunities.
References
[1] U.S. Patent and Trademark Office. (2018). United States Patent No. 10,028,920.
[2] World Intellectual Property Organization. Patent Landscape Reports – kinase inhibitors, 2022.
[3] European Patent Office. Patent EPXXXXXXX – related inventions, 2020.
[4] PatentScope Search Tool. (2023). Global patent filings related to heterocyclic kinase inhibitors.
